KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) FCF Margin (2016 - 2025)

Historic FCF Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 414.55%.

  • Nektar Therapeutics' FCF Margin fell 2296800.0% to 414.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 304.08%, marking a year-over-year decrease of 1131600.0%. This contributed to the annual value of 180.01% for FY2024, which is 346700.0% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' FCF Margin is 414.55%, which was down 2296800.0% from 409.62% recorded in Q2 2025.
  • Nektar Therapeutics' FCF Margin's 5-year high stood at 159.88% during Q4 2024, with a 5-year trough of 629.51% in Q4 2021.
  • In the last 5 years, Nektar Therapeutics' FCF Margin had a median value of 304.21% in 2021 and averaged 311.47%.
  • As far as peak fluctuations go, Nektar Therapeutics' FCF Margin surged by 3651700bps in 2022, and later plummeted by -2483200bps in 2025.
  • Over the past 5 years, Nektar Therapeutics' FCF Margin (Quarter) stood at 629.51% in 2021, then soared by 58bps to 264.34% in 2022, then increased by 25bps to 197.97% in 2023, then grew by 19bps to 159.88% in 2024, then tumbled by -159bps to 414.55% in 2025.
  • Its last three reported values are 414.55% in Q3 2025, 409.62% for Q2 2025, and 468.98% during Q1 2025.